BioPharm International

BioPharm International-12-01-2009
Volume: 22
Issue: 12

BioPharm International-11-02-2009
Volume: 2009 Supplement
Issue: 8

BioPharm International-11-01-2009
Volume: 22
Issue: 11

BioPharm International-10-03-2009
Volume: 2009 Supplement
Issue: 7

BioPharm International-10-02-2009
Volume: 2009 Supplement
Issue: 6

BioPharm International-10-01-2009
Volume: 22
Issue: 10

BioPharm International-09-01-2009
Volume: 22
Issue: 9

BioPharm International-09-02-2009
Volume: 2009 Supplement
Issue: 5

BioPharm International-08-01-2009
Volume: 22
Issue: 8

BioPharm International-07-01-2009
Volume: 22
Issue: 7

BioPharm International-06-01-2009
Volume: 22
Issue: 6

BioPharm International-06-02-2009
Volume: 2009 Supplement
Issue: 4

BioPharm International-05-01-2009
Volume: 22
Issue: 5

BioPharm International-04-01-2009
Volume: 22
Issue: 4

BioPharm International-04-02-2009
Volume: 2009 Supplement
Issue: 3

BioPharm International-03-01-2009
Volume: 22
Issue: 3

BioPharm International-03-02-2009
Volume: 2009 Supplement
Issue: 2

BioPharm International-02-01-2009
Volume: 22
Issue: 2

BioPharm International-01-02-2009
Volume: 2009 Supplement
Issue: 1

BioPharm International-01-01-2009
Volume: 22
Issue: 1

BioPharm International-12-01-2008
Volume: 21
Issue: 12

BioPharm International-11-02-2008
Volume: 2008 Supplement
Issue: 7

BioPharm International-11-01-2008
Volume: 21
Issue: 11

BioPharm International-10-02-2008
Volume: 2008 Supplement
Issue: 6

BioPharm International-10-01-2008
Volume: 21
Issue: 10

BioPharm International-09-01-2008
Volume: 21
Issue: 9

BioPharm International-08-01-2008
Volume: 21
Issue: 8

BioPharm International-07-01-2008
Volume: 21
Issue: 7

BioPharm International-06-01-2008
Volume: 21
Issue: 6

BioPharm International-06-02-2008
Volume: 2008 Supplement
Issue: 5
Advertisement
Advertisement
Trending on BioPharm International
1
Biocon’s Pebrilzo Becomes First Breast Cancer Treatment Biosimilar Approved Under EMA’s Tailored Clinical Approach
2
The BioPharm Brief: A Matrix-Targeting ADC in Head and Neck Cancer, an RNAi Approval in Myasthenia Gravis, and AbbVie Bets on AND-Gated Bispecifics
3
AbbVie and DISCO Partner on AND-Gated Bispecifics Designed to Recognize Tumor-Selective Protein Pairs
4
FDA Approves First RNAi Therapeutic for Generalized Myasthenia Gravis
5

